



We are pleased to report COVID-19 vaccine guidance has been simplified! Following FDA regulatory action, the CDC acted to streamline COVID-19 vaccine recommendations by authorizing single-shot BIVALENT vaccines. The original (monovalent) primary series COVID-19 vaccine is no longer authorized. At this stage of the pandemic, data supports simplifying the use of the authorized mRNA bivalent COVID-19 vaccines. The FDA/CDC will continue to monitor COVID-19 outbreaks and vaccine effectiveness in the months ahead and decisions about future vaccinations in the fall are forthcoming.



Monovalent No Longer Authorized

The original **MONOVALENT** Pfizer-BioNTech and Moderna (mRNA) COVID-19 vaccines are **NO longer authorized** for use in the United States. Consonus is no longer dispensing/administering this vaccine that was used for the primary series.

BIVALENT Pfizer-BioNTech and Moderna (mRNA) COVID-19 vaccines to be used for **ALL doses** administered to individuals 6 months of age and older.

Guidance

▷ **For Most Americans:**

If you have received ONE BIVALENT vaccine you are up to date.

▷ **If Unvaccinated or Only Received Monovalent (primary series):**

Individuals 6 years and older SHOULD receive 1 BIVALENT mRNA vaccine dose

▷ **If 65 Years and Older:**

If you have received a single dose of a bivalent vaccine, you MAY receive 1 additional dose at least **4 months** following the initial bivalent dose.

▷ **If Immunocompromised:**

If you have received a bivalent COVID-19 vaccine, you MAY receive a single additional dose of a bivalent COVID-19 vaccine at least **2 months** following the dose. (Additional doses may be given at discretion of, and at intervals determined by, the healthcare provider).